143 related articles for article (PubMed ID: 27246397)
1. Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.
Uchida M; Saeki K; Maeda S; Tamahara S; Yonezawa T; Matsuki N
J Vet Med Sci; 2016 Oct; 78(9):1515-1520. PubMed ID: 27246397
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
3. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
[TBL] [Abstract][Full Text] [Related]
4. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
[TBL] [Abstract][Full Text] [Related]
5. A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.
Takada M; Parys M; Gregory-Bryson E; Vilar Saavedra P; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2018 Mar; 18(1):237. PubMed ID: 29490634
[TBL] [Abstract][Full Text] [Related]
6. Serum level of apoptosis inhibitor of macrophage in dogs with histiocytic sarcoma and its association with the disease.
Uchida M; Matsumiya Y; Tsuboi M; Uchida K; Nakagawa T; Fujii W; Kobayashi T; Tsujimoto H; Ohmi A; Tomiyasu H; Motegi T; Maeda S; Momoi Y; Yonezawa T
Vet Comp Oncol; 2023 Sep; 21(3):391-400. PubMed ID: 37088561
[TBL] [Abstract][Full Text] [Related]
7. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
8. Utility of the second-generation curcumin analogue RL71 in canine histiocytic sarcoma.
Kelly B; Thamm D; Rosengren RJ
Vet Res Commun; 2024 Feb; 48(1):563-568. PubMed ID: 37597087
[TBL] [Abstract][Full Text] [Related]
9. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
[TBL] [Abstract][Full Text] [Related]
10. Variations in Histiocytic Differentiation of Cell Lines From Canine Cerebral and Articular Histiocytic Sarcomas.
Thongtharb A; Uchida K; Chambers JK; Nakayama H
Vet Pathol; 2017 May; 54(3):395-404. PubMed ID: 28178429
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Mason SL; Finotello R; Blackwood L
Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases expression in spontaneous canine histiocytic sarcomas and its xenograft model.
Fayyad A; Lapp S; Risha E; Pfankuche VM; Rohn K; Barthel Y; Schaudien D; Baumgärtner W; Puff C
Vet Immunol Immunopathol; 2018 Apr; 198():54-64. PubMed ID: 29571518
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
Kisseberth WC; Murahari S; London CA; Kulp SK; Chen CS
Am J Vet Res; 2008 Jul; 69(7):938-45. PubMed ID: 18593248
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs.
Kezer KA; Barber LG; Jennings SH
Vet Comp Oncol; 2018 Mar; 16(1):77-80. PubMed ID: 28419676
[TBL] [Abstract][Full Text] [Related]
15. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
Skorupski KA; Rodriguez CO; Krick EL; Clifford CA; Ward R; Kent MS
Vet Comp Oncol; 2009 Jun; 7(2):139-44. PubMed ID: 19453368
[TBL] [Abstract][Full Text] [Related]
17. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
[TBL] [Abstract][Full Text] [Related]
18. mRNA sequencing analysis and growth inhibitory effects of palbociclib on cell lines from canine histiocytic proliferative disorders.
Hirabayashi M; Chambers JK; Tani A; Tomiyasu H; Motegi T; Rimpo K; Nakayama H; Uchida K
Vet Comp Oncol; 2022 Sep; 20(3):587-601. PubMed ID: 35278028
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
Cannon C; Borgatti A; Henson M; Husbands B
J Small Anim Pract; 2015 Jul; 56(7):425-9. PubMed ID: 25828786
[TBL] [Abstract][Full Text] [Related]
20. Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma.
Tani H; Kurita S; Miyamoto R; Sawada H; Fujiwara-Igarashi A; Michishita M; Azakami D; Hasegawa D; Tamura K; Bonkobara M
J Am Anim Hosp Assoc; 2020; 56(3):146. PubMed ID: 32182105
[No Abstract] [Full Text] [Related]
[Next] [New Search]
